DrugPatentWatch Database Preview
Hydrogen peroxide - Generic Drug Details
» See Plans and Pricing
What are the generic sources for hydrogen peroxide and what is the scope of patent protection?
Hydrogen peroxide
is the generic ingredient in one branded drug marketed by Aclaris and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.Hydrogen peroxide has thirty patent family members in seventeen countries.
There are fifty-three drug master file entries for hydrogen peroxide.
Summary for hydrogen peroxide
International Patents: | 30 |
US Patents: | 6 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Drug Master File Entries: | 53 |
Bulk Api Vendors: | 133 |
Clinical Trials: | 83 |
Patent Applications: | 5,330 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price trends for hydrogen peroxide |
What excipients (inactive ingredients) are in hydrogen peroxide? | hydrogen peroxide excipients list |
DailyMed Link: | hydrogen peroxide at DailyMed |
Recent Clinical Trials for hydrogen peroxide
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Hospital Universitario San Ignacio | Phase 2/Phase 3 |
Pontificia Universidad Javeriana | Phase 2/Phase 3 |
The University of Texas Health Science Center, Houston | Phase 4 |
Medical Subject Heading (MeSH) Categories for hydrogen peroxide
US Patents and Regulatory Information for hydrogen peroxide
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
Aclaris | ESKATA | hydrogen peroxide | SOLUTION;TOPICAL | 209305-001 | Dec 14, 2017 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for hydrogen peroxide
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 2004518715 | Start Trial |
Austria | 397452 | Start Trial |
Mexico | 2016013826 | Start Trial |
South Korea | 20170029413 | Start Trial |
China | 106659643 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for hydrogen peroxide
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2523731 | 24/2020 | Austria | Start Trial | PRODUCT NAME: OSILODROSTAT ODER PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, EINSCHLIESSLICH OSILODROSTATDIHYDROGENPHOSPHAT; REGISTRATION NO/DATE: EU/1/19/1407 (MITTEILUNG) 20200113 |
3106463 | LUC00150 | Luxembourg | Start Trial | PRODUCT NAME: LAROTRECTINIB ET/OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER LE SULFATE DE LAROTRECTINIB, Y COMPRIS L'HYDROGENOSULFATE DE LAROTRECTINIB; AUTHORISATION NUMBER AND DATE: EU/1/19/1385 20190923 |
2523731 | LUC00159 | Luxembourg | Start Trial | PRODUCT NAME: OSILODROSTAT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, Y COMPRIS LE DIHYDROGENOPHOSPHATE D'OSILODROSTAT; AUTHORISATION NUMBER AND DATE: EU/1/19/1407 20200113 |
2523731 | 122020000026 | Germany | Start Trial | PRODUCT NAME: OSILODROSTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, EINSCHLIESSLICH OSILODROSTATDIHYDROGENPHOSPHAT; REGISTRATION NO/DATE: EU/1/19/1407 20200109 |
0605697 | SPC/GB01/008 | United Kingdom | Start Trial | PRODUCT NAME: 1-(((3-(2-(DIMETHYLAMINO)ETHYL)INDOL-5-YL)METHYL)SULFONYL)PYRROLIDINE GENERIC NAME ALMOTRIPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY AS ALMOTRIPTAN D,L - HYDROGEN MALATE; REGISTERED: ES 62.877 19991223; UK PL 16973/0005 20001026 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |